NGAL

The assays measure biomarkers — NGAL and KIM-1 — that the company said will help drug developers gauge the right dose for drugs in Phase I trials, validate proof-of-concept in Phase II, and confirm efficacy and safety in Phase III studies by helping avoid kidney damage in participants.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.